Việt Nam genomics market seen to be worth $482 million by 2030

Việt Nam genomics market seen to be worth $482 million by 2030

The Việt Nam genomics market is forecast to grow at a compounded annual rate of 16.73 per cent between 2023 and 2030 to top US$482.1 million, according to industry insiders.

Speakers at the “Success Story Session 2025: Pioneering Advances in Gene Sequencing in Việt Nam” event in HCM City last week. — Photo courtesy of DKSH

Speaking at an event titled “Success Story Session 2025: Pioneering Advances in Gene Sequencing in Việt Nam” in HCM City last week, Dr Nguyễn Thị Xuân Mai, senior manager, national sales, business unit technology, DKSH Vietnam, said market research shows that gene sequencing is experiencing robust growth, but challenges remain due to the specific characteristics of the market and the Vietnamese economy.

She said gene sequencing is a field of great interest, particularly in clinical research and treatment of cancer, rare diseases and genetic disorders.

Researchers and doctors hope that patients can access gene sequencing, allowing for a more accurate understanding of mutations and genetic disorders.

But its costs remain high, and the protocol is not covered by health insurance, making it difficult to expand its access.

Furthermore, Mai said, advanced gene sequencing equipment is still not widely available on the market.

As a market development service provider, DKSH aims to be the bridge between high-tech manufacturers like PacBio, a US life science technology company that designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems, and end users.

One of DKSH's key objectives is to raise market awareness, helping users understand the value of high-accuracy gene sequencing technologies. Once users recognise this value, they will see the long-term benefits of investing in gene sequencing equipment: increasing experiment accuracy, minimising errors, saving time and effort, and ultimately enhancing research efficiency and clinical applications, she said.

She underscored the significant growth opportunities in this field, saying: “As one of the fastest growing countries in life sciences and technology, Việt Nam is highly regarded for its potential to expand the gene sequencing market.

“Moreover, small and medium-sized enterprises are becoming increasingly aware of the importance of this technology.”

The current challenges are not only obstacles but also great opportunities for the gene sequencing market to grow strongly in the future, she noted.

Jennifer Hsu, associate sales director for North, South & Southeast Asia, PacBio, said in Việt Nam and other countries worldwide, short-read gene sequencing technology has become increasingly prevalent and extensively utilised.

It is also imperative to highlight the significance of long-read gene sequencing technology—HiFi, she said, pointing out that it addresses challenges, complexities and limitations inherent to short-read sequencing methods, she said.

This technological advancement significantly enhances applications in genetic research and the investigation of hereditary diseases, she added.

Mai said DKSH and PacBio have been working together since 2023 to enhance access to world-class sequencing technology in Việt Nam and across the region.

KTest, a pioneer in molecular biology, genetics and bioinformatics solutions in Việt Nam, has embraced PacBio’s Onso short-read sequencing system. This strategic investment boosts KTest’s operational productivity and cost efficiency.

Assoc. Prof. Dr. Hồ Huỳnh Thùy Dương, founder of KTest, spoke about some of the key projects the company has undertaken, including two medical research projects on genetic cardiomyopathy and others in the food industry and agriculture, reflecting the diverse research needs and practical applications of gene sequencing technology. 

Bizhub